GUTS FRACTYL HEALTH INC

Fractyl Health to Participate in the Upcoming December Conferences

Fractyl Health to Participate in the Upcoming December Conferences

BURLINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will present at two upcoming investor conferences.

Details of the presentations can be found below.

7th Annual Evercore ISI HealthCONx Conference

Format: Fireside Chat

Date: 12/03/2024

Time: 7:30 AM ET

Piper Sandler 36th Annual Healthcare Conference

Format: Fireside Chat

Date: 12/04/2024

Time: 1:30 PM ET

Webcast replays will be accessible following the live sessions on the Events page of the Investors section on the Company’s website at .

About Fractyl Health

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit .

Contacts 

Corporate Contact 

Lisa Davidson, Chief Financial Officer 

, 781.902.8800

Media Contact 

Jessica Cotrone, Corporate Communications

, 978.760.5622

Investor Contact

Stephen Jasper Gilmartin Group

, 619.949.3681



EN
26/11/2024

Underlying

GUTSFRACTYL HEALTH INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FRACTYL HEALTH INC

 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a D...

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateauedPreclinical results show that a single point-in-time treatment with RJVA-002 has the potential to achieve significant weight loss that can match or exceed best-in-class chronic drug therapy BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approach...

October 7, 2025 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Announces Pricing of $60 Million Underwritten Offering ...

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the pricing of an underwritten offering of 60 million shares of its common stock at a price of $1.00 per share. All of the securities are being of...

September 26, 2025 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Co...

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regain in sham-treated patients Revita procedure demonstrated excellent safety and tolerability to date, consistent with prior clinical studies Results validate pivotal study design and reinforce Revita’s potential to be the first therapy for post-GLP-1 weig...

September 26, 2025 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Expands Board of Directors with Appointments of Industr...

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors BURLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced the appointments of Christopher Thompson, M.D. and Ian Sheffield to its Board of Directors. These appointm...

September 3, 2025 1 EN
 PRESS RELEASE
Free
GUTS FRACTYL HEALTH ...

Fractyl Health Announces Second Quarter 2025 Financial Results and Bus...

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates Randomized 3-month REMAIN-1 Midpoint Cohort data expected in September 2025 Positive 3-month REVEAL-1 Cohort data showed single Revita® procedure sustained weight loss after GLP-1 discontinuation; incremental 6-month open-label data expected in Q4 2025 Top-line REMAIN-1 Pivotal Cohort 6-month data and PMA filing expected in H2 2026 $23M underwritten public offering expected to extend cash runway through key upcoming 3-and 6-month randomized data readouts from REMAIN-1 Midpoint Cohort Conference call tod...

August 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch